Recent advances in the pathophysiologic understanding of coronavirus disease 2019
(COVID-19) suggests that cytokine release syndrome (CRS) has an association with the …

Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150
000 patients in Germany alone. Methods This review is based on publications about current …

Background: The contemporary management of ambulatory ulcerative colitis (UC) continues
to be challenging with∼ 20% of children needing a colectomy within childhood years. We …

This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

Immune checkpoint inhibitors (ICIs) are effective in the treatment of patients with advanced
cancer and have emerged as a pillar of standard cancer care. However, their use is …

Inflammatory bowel diseases (IBDs) are chronic, immune-mediated disorders that include
Crohn's disease and ulcerative colitis. A pediatric onset of disease occurs in about 10% of …

Objective In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease
(CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …